Jazz Pharmaceuticals Ireland sues Sandoz Inc. in New Jersey federal court

description

Case Summary

JAZZ PHARMACEUTICALS IRELAND LIMITED and others filed a civil case against SANDOZ, INC. and others in the District of New Jersey, docket 24-cv-09110. No summary details are available. The case likely involves pharmaceutical patent or commercial disputes given the parties involved.

No timeline activity recorded yet. This page will grow as rulings and filings land.

Key Issues

• • Pharmaceutical litigation
• • Patent or commercial dispute
• • Complex civil litigation

smart_toy Juryvine case summary generated from primary court records. How we verify our work.

fact_check

Docket Snapshot

account_balance

Court

D.N.J.

District of New Jersey · 3rd Circuit · NJ

tag

Docket

Not captured

Civil

timeline

Stage

Active litigation

Active

event

Filed

Date unavailable

Not in the available feed

new_releases

Latest Filing

3:24-cv-09110 JAZZ PHARMACEUTICALS IRELAND LIMITED et al v. SANDOZ, INC. et al

Other · May 11, 2026

newspaper

Coverage

0 articles

0 sources tracked

groups

Participants

1 Plaintiff

2 linked entities

gavel

Judge

Not assigned in feed

What the record shows

This case is tied to District of New Jersey, a federal district court in NJ.

The newest docket activity we have is a other dated May 11, 2026.

The visible party/entity graph currently includes 3:24-cv-09110 JAZZ PHARMACEUTICALS IRELAND LIMITED and others.

No independent press coverage is attached yet; this page is currently docket-led rather than media-led.

About This Court

District of New Jersey (D.N.J.) is a federal district court in the 3rd Circuit, NJ.

Case Timeline

1 event

info

Other May 11, 2026

3:24-cv-09110 JAZZ PHARMACEUTICALS IRELAND LIMITED et al v. SANDOZ, INC. et al

Jazz Pharmaceuticals Ireland Limited filed a new case against Sandoz, Inc. and others, initiating litigation under docket number 3:24-cv-09110. This marks the formal start of a legal dispute, likely involving patent or pharmaceutical issues. Attorneys should monitor this case for potential impacts on pharmaceutical patent enforcement and generic competition.

description View filing open_in_new